Indeed, evidence exists for a high cost–benefit ratio for identifying patients with KRAS and BRAF wild-type metastatic colorectal cancer suitable for treatment with cetuximab and those with HER2-positive breast carcinomas who will respond to trastuzumab [34, 35]. The gene discussed is ERBB2; the disease is breast carcinoma.